X

用户登录

用户名
密 码
验证码
忘记密码?  注册用户
        
当前位置:首页->媒体报道

【海聚动态】北海康成参加CSCO乳腺癌年会,最新HER2阳性乳腺癌延长辅助治疗方案获各方关注

2018-04-16 14:09:06  信息来源:北海康成

  2018年4月12日,北海康成(北京)医药科技有限公司参加于北京召开的“2018中国临床肿瘤学会(CSCO)乳腺癌年会暨北京乳腺癌高峰论坛”。在这一具有重要影响力的专业学术交流会上,众多专业人士有机会了解最新治疗方案前沿信息,其中全球最新上市的HER2阳性乳腺癌延长辅助治疗药物且可口服的来那替尼获得了业内高度关注。

  根据官方统计,2015年中国新发乳腺癌患者数达27万,确诊及可接受治疗患者数约20万,其中HER2阳性乳腺癌患者约占总数的25%,HER2阳性乳腺癌复发后,晚期疾病进展较快。目前,国内仅有曲妥珠单抗与拉帕替尼获批针对HER2阳性乳腺癌的治疗。其中,无论HER2阳性乳腺癌术后辅助治疗还是HER2阳性转移性乳腺癌治疗,标准治疗方案均为曲妥珠单抗联合化疗。患者和医生对使用曲妥珠单抗后如何巩固治疗效果和降低复发风险有强烈的关注,而新的HER2阳性乳腺癌延长辅助治疗方案为医生和患者增加了更多治疗选择,具有很强的临床需求。

  北海康成致力于亚洲高发实体肿瘤治疗领域的创新型药物开发上市。2018年2月初,北海康成与Puma Biotechnology签署了乳腺癌口服药来那替尼在大中华地区进行开发和商业化的独占许可协议。来那替尼已于2017年7月获得美国FDA上市批准,用于HER2过度表达/扩增的早期乳腺癌成年患者接受以曲妥珠单抗为基础的辅助治疗后的延长辅助治疗。

  北海康成董事长及首席执行官,国家千人计划专家,薛群博士表示:“来那替尼已经进入美国NCCN指南,其适应症在我国有重大的临床需求。北海康成将全力以赴,尽快上市来那替尼,早日造福中国乳腺癌患者。”

海聚工程特聘专家简介

入选第十批海聚工程

JAMES XUE , Ph.D. , M.B.A.

FOUNDER , CHAIRMAN AND CEO 

Dr. James Xue is a veteran entrepreneur with extensive experience spans from US to China and from small biotech to multi-national biopharmaceutical companies. Over the last two decades, Dr. Xue led or was involved in several start-up companies and situations as well as managed sizable business and operations that contributed to his unique insight and deep knowledge in the biotech industry.

Dr. Xue built his biotech career by working for some of world’s most innovative companies in the San Francisco Bay Area and the Boston Area. Prior to CANbridge, he was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities. For five years he was founding general manager of Genzyme China during which he managed the launch of several life-saving drugs for the treatment of hematologic cancer and rare metabolic diseases in China including Thymoglobuline® and Cerezyme®. Dr. Xue was recognized as a distinguished expert entrepreneur by the “the Recruitment Program of Global Experts” (known as “the Thousand Talents Plan”) in 2016.

Dr. Xue holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He received executive training from INSEAD and Wharton Business School. Dr. Xue is a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.

来源:http://www.canbridgepharma.com/index/team

声明:凡本网注明“信息来源:某某某”的文/图等稿件,本网转载出于传递更多信息目的,本网站不对其观点或真实性负责,内容仅供参考。


友情链接: 北京双高国际人力资本集团 |  千人计划专家联谊会 |  千人计划网 |  中国人才网 |  北京人才工作网 | 
北京海外学人中心开发区分中心 |  北京海外学人中心CBD分中心

©Copyright By 2008-2015 北京海外学人中心 京ICP备14057082号 京公网安备110102000768 | 访问统计